The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

The use of RBL, a fecal microbiota-based live biotherapeutic, was safe and efficacious for recurrent CDI prevention in a large cohort of adults with common comorbidities.

Source: Focus Medica. Infection of the large intestine (colon) caused by the bacteria Clostridium difficile. Long-term use of antibiotics reduces the normal bacterial population in the intestine ...

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

Hidden beneath the surface, your bed linen may be home to millions of bacteria, fungi, mites, and viruses. These ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection. Investigators evaluated the safety and ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...